血液学中的微生物群改造:仍停留在实验室还是已可临床落地?
综述评估通过粪菌移植、益生菌及膳食益生元调节癌症患者微生物群的策略。粪菌移植用于恢复抗生素和化疗扰动后的微生物平衡,并治疗造血干细胞移植并发症如移植物抗宿主病和多重耐药菌定植;益生菌和益生元用于靶向调节以改善血液病结局。文中强调菌群失调在疾病、疗效和毒性中的作用,并评估其作为血液恶性肿瘤及HSCT患者新兴干预手段的前景。
要点
- 粪菌移植可能恢复抗生素和化疗后的微生物平衡并治疗HSCT并发症。
- 益生菌和膳食益生元是靶向调节微生物群以改善血液病结局的潜在策略。
- 菌群失调与疾病、治疗疗效和毒性相关,微生物群是独特可修饰的靶点。
核心结论
- 微生物群是潜在可修饰的靶点,粪菌移植、益生菌和益生元等改造策略在血液恶性肿瘤及HSCT患者中显示出前景,但尚需进一步评估其临床可行性。
研究设计与样本
- 综述,聚焦癌症患者微生物群组成和功能的改造策略,未报告系统检索范围或样本量。
主要发现
- 粪菌移植可用于恢复抗生素和化疗扰动后的微生物平衡,并治疗HSCT并发症如移植物抗宿主病和多重耐药菌定植。
- 益生菌和膳食益生元可用于靶向调节微生物群以改善血液病结局。
- 菌群失调在疾病、治疗疗效和毒性中发挥作用。
临床怎么用
- 可考虑将粪菌移植用于恢复抗生素或化疗后的微生物平衡,以及治疗HSCT后移植物抗宿主病和多重耐药菌定植。
- 可考虑使用益生菌或膳食益生元靶向调节微生物群,以改善血液病患者的结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Growing evidence suggests that human microbiota likely influence diverse processes including hematopoiesis, chemotherapy metabolism, and efficacy, as well as overall survival in patients with hematologic malignancies and other cancers. Both host genetic susceptibility and host-microbiota interactions may impact cancer risk and response to treatment; however, microbiota have the potential to be uniquely modifiable and accessible targets for treatment. Here, we focus on strategies to modify microbiota composition and function in patients with cancer. First, we evaluate the use of fecal microbiota transplant to restore microbial equilibrium following perturbation by antibiotics and chemotherapy, and as a treatment of complications of hematopoietic stem cell transplantation (HSCT), such as graft-versus-host disease and colonization with multidrug-resistant organisms. We then address the potential use of both probiotics and dietary prebiotic compounds in targeted modulation of the microbiota intended to improve outcomes in hematologic diseases. With each type of therapy, we highlight the role that abnormal, or dysbiotic, microbiota play in disease, treatment efficacy, and toxicity and evaluate their potential promise as emerging strategies for microbiota manipulation in patients with hematologic malignancies and in those undergoing HSCT.
引用
- Severyn CJ, Brewster R, Andermann TM, et al. Microbiota modification in hematology: still at the bench or ready for the bedside? Blood Adv. 2019. PMID: 31714965. doi:10.1182/bloodadvances.2019000365
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。